Leading pharma, biotech, and medtech innovators regularly turn to Carpmaels & Ransford LLP for high-profile UK and pan-European patent litigation, UPC actions and SPC litigation. The firm similarly excels in patent prosecution, IP transactions, and EPO opposition. The team is jointly led by patent prosecution-specialist Hugh Goodfellow; Ian Kirby, who advises on multijurisdictional patent litigation and IP disputes; and Matthew Georgiou, who focuses on market exclusivity. Also serving as co-heads, Jake Marshall handles IP and tech transactions; Mark Chapman manages biotech patent portfolios; John Brunner focuses on tech and medical devices EPO opposition; and Roger Lush handles the full trademark lifecycle. Camilla Balleny is no longer at the firm.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Hugh Goodfellow; Ian Kirby; Matthew Georgiou; Jake Marshall; Mark Chapman; John Brunner; Roger Lush
Other key lawyers
Edward Oates; Daniel Wise; Jennifer Antcliff; Stephen Duffield; Cameron Marshall; Simon Llewellyn; Selina Badiani; Aled Richards-Jones; Nikkie Xu; Sophie Leppington; David Holland; Paul Kaufman; Harvey Adams